- Email: [email protected]
SP104 – Mometasone furoate for perennial AR in elderly subjects
P126
Otolaryngology-Head and Neck Surgery, Vol 141, No 3S1, September 2009
METHODS: We used inferior turbinate mucosal samples from 10 patients with allergic rhinitis and 10 matched healthy control subjects. We extracted PEDF mRNA from the inferior turbinate mucosa samples and performed reverse transcription polymerase chain reaction analysis. We used western blotting to analyze differences in expression levels of PEDF protein between patients with allergic rhinitis and healthy controls, and the PEDF protein was localized immunohistochemically. RESULTS: The expression levels of PEDF mRNA and PEDF protein in the nasal mucosa were significantly increased in patients with allergic rhinitis compared with those in nonallergic controls. The PEDF protein was expressed in the epithelium and submucosal glands. CONCLUSIONS: We found that PEDF protein is expressed in the human nasal mucosa, and its expression is increased in allergic rhinitis. These results suggest a possible contribution of PEDF to the chronic inflammation of the nasal mucosa in allergic rhinitis. SP104 – Mometasone furoate for perennial AR in elderly subjects Jay Grossman (presenter); Gokul Gopalan, MD, MPH OBJECTIVES: 1) Examine the efficacy of mometasone furoate nasal spray (MFNS) in elderly subjects with perennial allergic rhinitis (PAR). 2) Demonstrate the safety of MFNS in this patient population. METHODS: This multicenter, double-blind, placebo-controlled study randomized subjects at least 65 years old with PAR to MFNS 200mcg once daily or placebo for 12 weeks. Subjects recorded individual symptom scores (0 ⫽ none, 3 ⫽ severe) twice daily: morning (before dosing) and evening. Primary endpoint was average change in total nasal symptom score (TNSS: sum of individual symptom scores) from baseline over days 1-15. Data analyses were conducted on efficacy and intention-to-treat (ITT) populations. RESULTS: 314 subjects were in the efficacy population (MFNS ⫽ 162, placebo ⫽1 52) and 334 were in the ITT population (MFNS ⫽ 170, placebo ⫽ 164). Mean baseline age was 71 (range: 65-85) for MFNS and 70 (range: 65-87) for placebo. Most had moderate disease (MFNS: 89%, placebo: 88%). Mean decrease in TNSS in efficacy population at day 15 was 17% (mean change ⫽ -1.1) with MFNS vs 11% (-0.7) with placebo (p ⫽ 0.03). For ITT population, mean decrease in TNSS was 16% (mean change ⫽ -1.1) for MFNS vs 11% (-0.7) for placebo (p ⫽ 0.03). No serious treatment-related adverse events or clinically meaningful changes in electrocardiograms, vital signs, or laboratory tests. CONCLUSIONS: MFNS 200 mcg once daily safely and effectively reduces PAR symptoms in elderly subjects.
SP102 – The effect of allergic rhinitis on degree of stress and fatigue Dae Han Chung, MD (presenter); Seung Youp Shin; Kun Hee Lee; Sung Wan Kim, MD, PhD; Joong Saeng Cho, MD, PhD OBJECTIVES: Allergic rhinitis is a well known disease that increases patients’ stress and fatigue, and so does obstructive sleep apnea. But there are no studies showing the result if both diseases coexist. In our study, we evaluated the amount of stress and fatigue when allergic rhinitis is combined with obstructive sleep apnea. METHODS: Thirty-four people who were diagnosed with obstructive sleep apnea were enrolled in our study. Among them, 12 people were classified into allergic rhinitis group and 22 people to control group. We evaluated RQLQ, ESS, stress score, fatigue score, and ability to cope with stress with questionnaires, and statistically compared mean scores of both groups. RESULTS: There were no significant differences in BMI, RDI, or RERA between the two groups. Mean RQLQ scores of allergic rhinitis group were 53.1 and control group was 26.4. Mean fatigue scores were 38.8 and 29.9 each, which were significantly higher in allergic rhinitis group. Allergic rhinitis group showed higher stress score, decreased ability to cope with stress, and higher mean ESS, but they were not significant. Ten people out of 12 in allergic rhinitis group and nine people of 22 in control group needed surgical treatment for obstructive sleep apnea. CONCLUSIONS: Allergic rhinitis can aggravate fatigue in obstructive sleep apnea patients and also might be a worsening factor of stress. The patients who have both allergic rhinitis and obstructive sleep apnea might need more careful management, and further study about this should be performed.
Facial Plastic and Reconstructive Surgery SP129 – A novel rat model of osteoradionecrosis of the mandible Marc Cohen, MD, MS (presenter); Vishad Nabili, MD; Ichiro Nishimura, DDS, DMSc, DMD, FAP; Akishige Hokugo, DDS, PhD; John Beumer III, DDS, MS; Elliot Abemayor, MD, PhD; Guy Juillard, MD OBJECTIVES: 1) To create an animal model for the study of osteoradionecrosis of the mandible. 2) To demonstrate the efficacy of using high dose rate (HDR) brachytherapy for rat mandible irradiation. METHODS: Ten Sprague-Dawley male rats were used in this study. In all rats, a brachytherapy catheter was inserted subcutaneously along the left half of the mandible. Seven rats received a single dose of 20 Gy using an HDR after-loading
Words and degrees that may be missing from abstracts in this program are due to limitations in the submission process. Continuing improvements in that database are still in process, and a serious attempt has been made to correct missing content. For the latest information about the annual meeting, and to access the new Itinerary Planner for your visit, please go to: www.entnet.org/annual_meeting.
Otolaryngology-Head and Neck Surgery, Vol 141, No 3S1, September 2009
METHODS: We used inferior turbinate mucosal samples from 10 patients with allergic rhinitis and 10 matched healthy control subjects. We extracted PEDF mRNA from the inferior turbinate mucosa samples and performed reverse transcription polymerase chain reaction analysis. We used western blotting to analyze differences in expression levels of PEDF protein between patients with allergic rhinitis and healthy controls, and the PEDF protein was localized immunohistochemically. RESULTS: The expression levels of PEDF mRNA and PEDF protein in the nasal mucosa were significantly increased in patients with allergic rhinitis compared with those in nonallergic controls. The PEDF protein was expressed in the epithelium and submucosal glands. CONCLUSIONS: We found that PEDF protein is expressed in the human nasal mucosa, and its expression is increased in allergic rhinitis. These results suggest a possible contribution of PEDF to the chronic inflammation of the nasal mucosa in allergic rhinitis. SP104 – Mometasone furoate for perennial AR in elderly subjects Jay Grossman (presenter); Gokul Gopalan, MD, MPH OBJECTIVES: 1) Examine the efficacy of mometasone furoate nasal spray (MFNS) in elderly subjects with perennial allergic rhinitis (PAR). 2) Demonstrate the safety of MFNS in this patient population. METHODS: This multicenter, double-blind, placebo-controlled study randomized subjects at least 65 years old with PAR to MFNS 200mcg once daily or placebo for 12 weeks. Subjects recorded individual symptom scores (0 ⫽ none, 3 ⫽ severe) twice daily: morning (before dosing) and evening. Primary endpoint was average change in total nasal symptom score (TNSS: sum of individual symptom scores) from baseline over days 1-15. Data analyses were conducted on efficacy and intention-to-treat (ITT) populations. RESULTS: 314 subjects were in the efficacy population (MFNS ⫽ 162, placebo ⫽1 52) and 334 were in the ITT population (MFNS ⫽ 170, placebo ⫽ 164). Mean baseline age was 71 (range: 65-85) for MFNS and 70 (range: 65-87) for placebo. Most had moderate disease (MFNS: 89%, placebo: 88%). Mean decrease in TNSS in efficacy population at day 15 was 17% (mean change ⫽ -1.1) with MFNS vs 11% (-0.7) with placebo (p ⫽ 0.03). For ITT population, mean decrease in TNSS was 16% (mean change ⫽ -1.1) for MFNS vs 11% (-0.7) for placebo (p ⫽ 0.03). No serious treatment-related adverse events or clinically meaningful changes in electrocardiograms, vital signs, or laboratory tests. CONCLUSIONS: MFNS 200 mcg once daily safely and effectively reduces PAR symptoms in elderly subjects.
SP102 – The effect of allergic rhinitis on degree of stress and fatigue Dae Han Chung, MD (presenter); Seung Youp Shin; Kun Hee Lee; Sung Wan Kim, MD, PhD; Joong Saeng Cho, MD, PhD OBJECTIVES: Allergic rhinitis is a well known disease that increases patients’ stress and fatigue, and so does obstructive sleep apnea. But there are no studies showing the result if both diseases coexist. In our study, we evaluated the amount of stress and fatigue when allergic rhinitis is combined with obstructive sleep apnea. METHODS: Thirty-four people who were diagnosed with obstructive sleep apnea were enrolled in our study. Among them, 12 people were classified into allergic rhinitis group and 22 people to control group. We evaluated RQLQ, ESS, stress score, fatigue score, and ability to cope with stress with questionnaires, and statistically compared mean scores of both groups. RESULTS: There were no significant differences in BMI, RDI, or RERA between the two groups. Mean RQLQ scores of allergic rhinitis group were 53.1 and control group was 26.4. Mean fatigue scores were 38.8 and 29.9 each, which were significantly higher in allergic rhinitis group. Allergic rhinitis group showed higher stress score, decreased ability to cope with stress, and higher mean ESS, but they were not significant. Ten people out of 12 in allergic rhinitis group and nine people of 22 in control group needed surgical treatment for obstructive sleep apnea. CONCLUSIONS: Allergic rhinitis can aggravate fatigue in obstructive sleep apnea patients and also might be a worsening factor of stress. The patients who have both allergic rhinitis and obstructive sleep apnea might need more careful management, and further study about this should be performed.
Facial Plastic and Reconstructive Surgery SP129 – A novel rat model of osteoradionecrosis of the mandible Marc Cohen, MD, MS (presenter); Vishad Nabili, MD; Ichiro Nishimura, DDS, DMSc, DMD, FAP; Akishige Hokugo, DDS, PhD; John Beumer III, DDS, MS; Elliot Abemayor, MD, PhD; Guy Juillard, MD OBJECTIVES: 1) To create an animal model for the study of osteoradionecrosis of the mandible. 2) To demonstrate the efficacy of using high dose rate (HDR) brachytherapy for rat mandible irradiation. METHODS: Ten Sprague-Dawley male rats were used in this study. In all rats, a brachytherapy catheter was inserted subcutaneously along the left half of the mandible. Seven rats received a single dose of 20 Gy using an HDR after-loading
Words and degrees that may be missing from abstracts in this program are due to limitations in the submission process. Continuing improvements in that database are still in process, and a serious attempt has been made to correct missing content. For the latest information about the annual meeting, and to access the new Itinerary Planner for your visit, please go to: www.entnet.org/annual_meeting.